Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2025 Apr 24, 11:55

BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation ...

BioNTech SE
Webhose 2025 Apr 24, 11:55

BioNTech SE (BNTX) Showcases Oncology Pipeline Progress at AACR 2025 | BNTX stock news

BioNTech SE
Webhose 2025 Apr 24, 11:16

8,767 Shares in BioNTech SE (NASDAQ:BNTX) Acquired by Diadema Partners LP

BioNTech SE
Webhose 2025 Apr 24, 11:10

BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025 | The Manila Times

BioNTech SE
Webhose 2025 Apr 23, 17:19

BioNTech (BNTX) to Announce Q1 2025 Financial Results

BioNTech SE
Webhose 2025 Apr 23, 17:19

BioNTech (BNTX) Advances Cancer Treatment Trials and IP Defense

BioNTech SE
Webhose 2025 Apr 23, 10:48

Q1 Earnings Forecast for BioNTech Issued By Leerink Partnrs

BioNTech SE
Webhose 2025 Apr 23, 08:42

Marshall Wace LLP Increases Holdings in BioNTech SE (NASDAQ:BNTX)

BioNTech SE
Webhose 2025 Apr 22, 12:01

BioNTech SE to Announce Q1 2025 Financial Results | BNTX stock news

BioNTech SE
Webhose 2025 Apr 22, 11:05

BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025 | The Manila Times

BioNTech SE
Webhose 2025 Apr 21, 20:37

BioNTech SE (BNTX) Q4 2024 Earnings Call Highlights: Navigating Challenges and Advancing Innovations

BioNTech SE
Webhose 2025 Apr 21, 09:00

Bridgewater Associates LP Increases Holdings in BioNTech SE (NASDAQ:BNTX)

BioNTech SE
Webhose 2025 Apr 19, 11:40

BioNTech SE (NASDAQ:BNTX) Shares Sold by Capital International Inc. CA

BioNTech SE
Webhose 2025 Apr 18, 10:01

Finward Bancorp Makes New Investment in BioNTech SE (NASDAQ:BNTX)

BioNTech SE
Webhose 2025 Apr 18, 07:26

What the Newest mRNA Vaccines Could Do Beyond COVID

BioNTech SE
Webhose 2025 Apr 14, 17:34

BioNTech (NasdaqGS:BNTX) Sees 11% Stock Increase Over Last Week

BioNTech SE
Webhose 2025 Apr 14, 17:32

BioNTech (BNTX) Dominates German Stocks Among Hedge Funds

BioNTech SE
Webhose 2025 Apr 13, 11:52

BioNTech SE (NASDAQ:BNTX) Shares Sold by Quinn Opportunity Partners LLC

BioNTech SE
Webhose 2025 Apr 13, 10:27

Scotia Capital Inc. Acquires 30,143 Shares of BioNTech SE (NASDAQ:BNTX)

BioNTech SE
Webhose 2025 Apr 11, 00:00

Sen. Johnson demands COVID vaccine makers hand over all documents, communications, as evidence against their products reaches a climax - NaturalNews.com

BioNTech SE
Webhose 2025 Apr 09, 08:30

Franklin Resources Inc. Buys 133,402 Shares of BioNTech SE (NASDAQ:BNTX)

BioNTech SE
Webhose 2025 Apr 06, 09:07

Cinctive Capital Management LP Buys Shares of 14,760 BioNTech SE (NASDAQ:BNTX)

BioNTech SE
Webhose 2025 Apr 02, 19:37

Is BioNTech SE (BNTX) the Best German Stock to Buy According to Hedge Funds?

BioNTech SE
Webhose 2025 Apr 02, 12:01

BioNTech (NASDAQ:BNTX) Price Target Cut to $145.00 by Analysts at HC Wainwright

BioNTech SE
Webhose 2025 Apr 02, 11:07

Groupama Asset Managment Buys 19,994 Shares of BioNTech SE (NASDAQ:BNTX)

BioNTech SE
Webhose 2025 Apr 02, 06:30

BioNTech SE (NASDAQ:BNTX) Receives Consensus Rating of "Moderate Buy" from Brokerages

BioNTech SE
Webhose 2025 Apr 01, 17:17

BioNTech (NASDAQ:BNTX) Shares Gap Down - Time to Sell?

BioNTech SE
Webhose 2025 Mar 29, 15:50

Analysts' Top Healthcare Picks: Ascentage Pharma Group International Unsponsored ADR (AAPG), BioNTech SE (BNTX) | Markets Insider

BioNTech SE
Webhose 2025 Mar 28, 10:26

Mitsubishi UFJ Trust & Banking Corp Has $21.37 Million Position in BioNTech SE (NASDAQ:BNTX)

BioNTech SE
Webhose 2025 Mar 28, 10:17

CureVac (CVAC) Rises 10% After Key Patent Victory; Other Movers

BioNTech SE
Webhose 2025 Mar 28, 01:32

European Patent Office declares CureVac mRNA patent valid

BioNTech SE
Webhose 2025 Mar 27, 22:26

CureVac (CVAC) Surges as European Court Validates Key Patent

BioNTech SE
Webhose 2025 Mar 27, 20:47

CORRECT: CureVac Says Patent Validated in Dispute With BioNTech

BioNTech SE

Latest news

Frances Wang 2025 Apr 24, 16:00

Exchange Traded Funds News: Tech-Focused ETFs Gain Traction Amid AI Boom

ETFs
Tommy Yap 2025 Apr 24, 16:00

Morning Note: US-China Trade Deadlock; Nvidia's AI Leap; Canada Votes

Morning Note CAD Forex
Frances Wang 2025 Apr 23, 16:00

Hang Seng Index Gains on Strong China GDP amid Trump Tariffs Uncertainty

Indices
Frances Wang 2025 Apr 23, 16:00

Forex news today: GBP/USD gains, USD/JPY declines, EUR/USD strengthens

Forex
Frances Wang 2025 Apr 23, 16:00

Trending stocks to watch: AMD, GOOG, NVDA, AMZN, MSFT

Stocks
Tommy Yap 2025 Apr 23, 16:00

Morning Note: Tariff Deadlock Grips US-China Trade; Alphabet's Report Looms; BOJ Dilemma

Morning Note Tech
Frances Wang 2025 Apr 22, 16:00

Commodity market today: Crude Oil Fluctuates as OPEC+ Modifies Production Goals

Commodities
Tommy Yap 2025 Apr 22, 16:00

Morning Note: Trump Calms Fed Fears; Tesla Disappoints; UK Trade Talks Begin

Morning Note Tech

Info

Spread

0.8925

Spread (%)

0.7439 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Friday

13:31 - 19:59

Monday

13:31-19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

27604328448

Shares Outstanding

240392992

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-3.47

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments
Trustpilot